Not just blood sugar and cholesterol: Top diabetologist lists 5 biomarkers to predict diseases years before symptoms appear

When we people think about heart-disease risk — especially among those with diabetes or metabolic problems — we immediately consider checking blood sugar and cholesterol levels. Sure, if any of these lie in the “abnormal” bracket — we know what’s coming, and we take precautionary measures based on that.

But what if this familiar duo only captures part of the story?

In recent years, researchers have been talking about other blood and urine markers — biomarkers — that can indicate rising risk long before a person feels sick. Measuring these markers can give a clearer, earlier picture of who is likely to develop heart disease, stroke, or metabolic complications years down the line.

For patients, this opens an avenue for awareness and a scope for preventative measures — a chance to act sooner with lifestyle changes, targeted medicines, or closer monitoring.

But what are those biomarkers that we usually miss?

According to one of the top diabetologists in India, Dr Brijmohan Arora, there are five deeper-level biomarkers worth checking that are not commonly included in routine health checkups — and yet, they can signal future disease risk long before any symptoms arise.

ApoB measures the number of cholesterol-carrying particles that are “atherogenic,” meaning they can penetrate artery walls and drive plaque formation. According to Dr Arora, ApoB is “The single most accurate marker for heart-attack risk.”

Unlike LDL (which estimates fat quantity), ApoB reflects the particle count — two people may have the same LDL level but very different numbers of particles. The one with higher ApoB has more “bullets” cruising through the arteries, raising risk. Medical literature supports that ApoB outperforms LDL-C in risk prediction, especially in people with metabolic conditions.

hs-CRP is a sensitive marker of inflammation — specifically, low-grade chronic inflammation that often quietly damages blood vessels. Elevated hs-CRP has consistently been associated with increased risk of heart attack, stroke, and cardiovascular death, even in people without prior disease.

Because inflammation underlies atherosclerosis and plaque instability, hs-CRP helps capture risk that traditional lipid panels miss. Including hs-CRP alongside cholesterol improves the accuracy of risk assessments.

Homocysteine is an amino acid in the blood. When elevated — a condition known as Hyperhomocysteinemia — it is linked to damage of the inner lining of arteries, increased oxidative stress, and a greater chance of heart disease, blood clots, or stroke.

Studies show that higher homocysteine levels — even without overt cholesterol abnormalities — are associated with cardiovascular and metabolic risk, particularly in people with diabetes or other metabolic disorders.

While blood sugar or HbA1c tests reveal current glucose levels or 3-month averages, fasting insulin shows how hard the pancreas is working to keep sugar under control. Elevated fasting insulin often signals early insulin resistance — a precursor to prediabetes, type-2 diabetes, fatty-liver disease, and other metabolic disorders. According to Dr Arora, this test signals “The earliest sign of insulin resistance, even before sugar rises.”

Detecting insulin resistance early helps individuals take corrective action — lifestyle, diet, exercise — potentially preventing progression to overt diabetes and associated cardiovascular risk.

The Omega-3 Index measures the proportion of long-chain omega-3 fatty acids (EPA + DHA) in the red-blood-cell membranes. A higher Omega-3 Index is associated with lower inflammation, better metabolic health, and reduced risk of coronary heart disease and total mortality.

Low omega-3 levels correlate with poor glucose metabolism — independent of body mass index (BMI) — suggesting its value even in non-obese individuals.

According to Dr Arora, this index offers deep insight into long-term cell health, inflammation status, and heart protection — making it a valuable marker for proactive health screening.

First and foremost, request advanced screening. If you have diabetes, prediabetes, metabolic syndrome, or a family history of heart disease, asking your doctor for tests beyond the standard panel — including ApoB, hs-CRP, homocysteine, fasting insulin, and Omega-3 Index — may help detect hidden risk early.

Secondly, use the results for prevention. Elevated values don’t guarantee disease, but they signal elevated risk. With early warning, you can focus on lifestyle changes (diet, exercise, sleep, omega-3 intake), controlling inflammation, insulin sensitivity, and vascular health — potentially before major damage occurs.

Additionally, combine markers for better assessment. Single-marker tests are helpful, but combining several of these biomarkers gives a more comprehensive and sensitive snapshot of cardiovascular and metabolic risk than traditional glucose or cholesterol alone.

Finally, reassess periodically. Since metabolism and diet change over time, periodic monitoring can help you track how lifestyle affects risk and adjust accordingly.

While markers such as ApoB, hs-CRP, and homocysteine are backed by substantial evidence, others — like Omega-3 Index or fasting insulin — have variable data and are not yet uniformly part of clinical guidelines everywhere. Clinical trials on omega-3 supplementation have had mixed results.

Additionally, elevated biomarkers indicate risk, but they don’t guarantee disease — they reflect probability. Factors like genetics, environment, lifestyle, and co-morbidities also influence outcomes. Besides, access and cost may limit such comprehensive screening. Not all labs offer Omega-3 index tests or measure ApoB routinely, especially in resource-constrained settings.

Furthermore, it’s important to note that biomarker values must be interpreted in context — one elevated value alone may not warrant alarm; a pattern and follow-up matter.